Publications by authors named "Roisin Puentes"

Introduction: PD-L1 immunohistochemistry (IHC) is being used as a predictive marker of the benefit derived from immunotherapy in several cancer types, including breast cancer. However, the insight gleaned of the prognostic and predictive value of PD-L1 status and its correlation with molecular characteristics during breast cancer progression remains limited.

Methods: We performed an PD-L1 (22C3) assay in pre-treatment primary and metastatic tumor sections from 33 patients with breast carcinoma, matched for post neoadjuvant chemotherapy (p-NACT).

View Article and Find Full Text PDF

Purpose: The International Ki67 Working Group (IKWG) has developed training for immunohistochemistry (IHC) scoring reproducibility and recommends cut points of ≤ 5% and ≥ 30% for prognosis in ER+, HER2-, stage I/II breast cancer. We examined scoring reproducibility following IKWG training and evaluated these cut points for selecting patients for further testing with the 21-gene Recurrence Score (RS) assay.

Methods: We included 307 women aged 50+ years with node-negative, ER+PR+HER2- breast cancer and with available RS results.

View Article and Find Full Text PDF
Article Synopsis
  • Plekha7 is a protein that helps cells stick together and keep strong barriers, which is important for cell health, especially in the lining of the intestines.
  • In colorectal cancer, levels of Plekha7 are higher than normal and increase as the cancer gets worse.
  • Plekha7 works better with normal KRas proteins than with mutated ones, and stopping Plekha7 can slow down the growth of tumors caused by mutated KRas.
View Article and Find Full Text PDF

Cnk1 (connector enhancer of kinase suppressor of Ras 1) is a pleckstrin homology (PH) domain-containing scaffold protein that increases the efficiency of Ras signaling pathways, imparting efficiency and specificity to the response of cell proliferation, survival, and migration. Mutated KRAS (mut-KRAS) is the most common proto-oncogenic event, occurring in approximately 25% of human cancers and has no effective treatment. In this study, we show that selective inhibition of Cnk1 blocks growth and Raf/Mek/Erk, Rho and RalA/B signaling in mut-KRAS lung and colon cancer cells with little effect on wild-type (wt)-KRAS cells.

View Article and Find Full Text PDF